Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Experts say the drug will give thousands of vulnerable infants “their own suit of armour” for their first winter ...

Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season.